Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

2024; Elsevier BV; Linguagem: Inglês

10.1016/j.abd.2024.08.002

ISSN

1806-4841

Autores

Tânia Ferreira Cestari, Cacilda da Silva Souza, Luna Azulay‐Abulafia, Ricardo Romiti, André Vicente Esteves de Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antônio, Lincoln Zambaldi Fabricio, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra Song, Jasmina Kalabic, N. P. del Castillo Martín, Luiza Keiko Matsuka Oyafuso,

Tópico(s)

Autoimmune Bullous Skin Diseases

Resumo

Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit.

Referência(s)